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Background: Statin treatment has increased also among people aged 80 years and over, but adverse effects 
potentially promoting frailty and loss of resilience are frequent concerns. 
 
Methods: In the Helsinki Businessmen Study (HBS), men born in 1919-1934 (original n=3490), have been 
followed-up since the 1960s. In 2011, a random subcohort of home-living survivors (n=525) was assessed 
using questionnaires, and clinical (including identification of phenotypic frailty) and laboratory 
examinations. A 7-year mortality follow-up ensued. 
 
Results: We compared 259 current statin users (median age 82 years, interquartile range 80 to 85 years) 
with 266 nonusers (83; 80 to 86 years). Statin users had significantly more multimorbidity than nonusers 
(prevalencies 72.1% and 50.4%, respectively, P<0.0001) and worse glucose status than nonusers 
(prevalencies of diabetes 19.0% and 9.4%, respectively, P=0.0008). However, there was no difference in 
phenotypic frailty (10.7% vs 11.2%, P=0.27), and statin users had higher plasma prealbumin level than 
nonusers (mean levels 257.9 and 246.3 mg/L, respectively, P=0.034 adjusted for age, body mass index and 
C-reactive protein) implying better nutritional status. Despite morbidity difference, age-adjusted 7-year 
mortality was not different between the two groups (98 and 103 men among users and nonusers of statins, 
respectively,  hazard ratio 0.96, 95% confidence interval 0.72-1.30).   
 
Conclusions: Our study suggests that male octogenarian statin users preserved resilience and survival 
despite multimorbidity, and this may be associated with better nutritional status among statin users. 
 








    Community-living octogenarian statin users have survival benefit despite multimorbidity and may be 
associated with nutrition. 
    Possible contributor to the resilience with statins was the significantly higher prealbumin level pertaining 
to better nutrition. 
    Phenotypic frailty and quality of life measurements showed non-significant differences among statin 
users and nonusers. 
 
  
Although randomised treatment trials are lacking, statin treatment is common among octogenarians (1, 2). 
In any age group, effects of treatments on overall health status, functioning and wellbeing are important to 
consider (1). Several concerns on statin treatment in older people, especially over 80 years of age, have 
been expressed, and these include risk of musculoskeletal pain impairing function, development of 
diabetes (2, 3, 4, 5, 6), and the epidemiologic finding of low cholesterol associating with higher mortality (7, 
8). It is thus feared that statin treatment -- despite beneficial effects in younger adults -- could impair 
resilience among oldest-old patints. 
 
However, cholesterol levels may decrease in older people because of nutritional deficiencies or 
unintentional weight loss (one component of frailty), and chronic diseases leading to inflammaging (9, 10). 
We have previously reported from the Helsinki Businessmen Study (HBS, a cohort of men born in 1919-
1934) that statin treatment is not associated with impaired health-related quality of life (HRQoL) in 
octogenarian men (11). Moreover, there was less weight loss in older statin users compared to nonusers 
(12), which may be a favourable feature in people prone to frailty. Interestingly, hydroxymethyl coenzyme 
A reductase (HMGCR) gene variation has been reported to be associated with higher body-mass index 
(BMI), which could also affect type 2 diabetes risk (T2DM) (13). Statin treatment and HMGCR gene variation 
were both associated with body weight gain and higher risk for T2DM, but the magnitude of body-weight 
change was insufficient to account for the increased T2DM risk. Furthermore, the link between the 
reported gene variation and insulin/glucose concentrations supported body-weight mediated association of 
HMGCR inhibition with insulin resistance. 
 
In the present analysis we aimed to characterise multidomain associations of statin treatment with 
lifestyle, frailty and morbidity, as well as nutritional, metabolic, and inflammatory markers, among 
community-dwelling octogenarian men of the HBS cohort. We also related statin use to 7-year mortality 







Study Population and Measurements 
 
These are secondary analyses of the HBS, a cohort of men born 1919 to 1934 (original n=3490), who have 
been followed-up since the 1960s. Their cardiovascular disease risk factor history (including fasting serum 
cholesterol and one-hour post-load glucose values) is known since midlife (mean age 40 years), and the 
cohort has been followed-up with regular postal questionnaires including reported medication since the 
year 2000 (14).  In 2010/11, current addresses were retrieved from the Population Information System of 
Finland for 907 surviving HBS participants, and a questionnaire survey about lifestyle, medications, 
prevalent physician-diagnosed diseases, and HRQoL (RAND-36/SF-36 instrument, 
https://www.rand.org/health/surveys_tools/mos/36-item-short-form.html, 11) was sent to them. 
 
In that wave, the questionnaire was returned by 615 men (67.8% response rate), and clinical and laboratory 
examinations were performed in a random subcohort of 525 men (consort diagram is shown in Appendix 
Figure 1). Statin users and nonusers were compared using multidomain variables presented in Appendix 
Table 1. Body mass index (BMI) was defined as weight (kg) divided by midlife height (m) squared), waist 
circumference was measured at the upper level of the pelvic crest. Morbidity was assessed from nine self-
reported diseases (diabetes, hypertension, coronary artery disease, cerebrovascular disease, peripheral 
artery disease, heart failure, chronic obstructive lung disease, cancer, and musculoskeletal disease) and 
multimorbidity was defined as 2 or more concomitant diseases. The prevalence of phenotypic prefrailty 
and frailty was assessed using a modified Fried method as described earlier (15). A total score of 3 or more 
defined frailty, a score of 1 or 2 defined pre-frailty, and 0 indicated nonfrailty. Peak expiratory flow (PEF) 
was measured 3 times and mean value used for analyses. 
 
 Walk speed was measured in 10 meters. Laboratory examinations were performed after a 12 h fast and 
analysed by the certified laboratory of the Oulu University Hospital (Oulu, Finland). Indices were calculated 
to reflect glucose metabolism: quantitative insulin sensitivity check index (QUICK = 1 / log(fasting insulin 
µU/mL) + log(fasting glucose mg/dL), and homeostatic model assessment – insulin resistance (HOMA-IR 
with glucose in molar units = [glucose x insulin]/22.5). 
 
Total mortality up to 31 March 2018 was retrieved from the Finnish Population Information System. The 
follow-up has been approved by the ethical committee of the Department of Medicine, Helsinki University 




Descriptive statistics, Armitage test for trend in proportions, and analysis of covariance (ANCOVA) were 
used to compare statin users with nonusers. The ANCOVA analyses (reporting means with standard errors 
[SE] in the statistical package) were primarily adjusted for age to study multidomain variables. The analysis 
of prealbumin among statin users and nonusers was further adjusted for age, BMI and C-reactive protein 
(CRP). RAND-36 scales were analysed  using ANCOVA  to compare statin users and nonusers and were 
primary adjusted for age, multimorbidity was added in the model when feasible. Multiple testing was 
adjusted using Bonferroni’s correction procedure. Assumptions of Cox regression were met and it was used 
to study proportional hazard ratios [HR] with 95% confidence intervals [CI] for factors affecting follow-up 
mortality. The model included statin usage, age and was additionally adjusted for midlife cholesterol and 
current morbidity. Statistical significance was set at P < 0.05. Statistical analyses were performed using 




We compared the 259 men currently on statin treatment (median age 82, interquartile range 80 to 85 
years) with the 266 men not using statins (median age 83; interquartile range 80 to 86 years); their 
multidomain characteristics are compared in Table 1. Of the statin users in 2010/11, 32.3% and 91.8% 
reported statin use also in 2000 and 2007, respectively; among nonusers the respective proportions were 
3.8% and 19.2%. Overall, statin users were sicker than nonusers, especially for cardiovascular diseases and 
diabetes. Consequently, statin users had also more multimorbidity than nonusers (prevalence 72.1% versus 
50.4%, P<0.0001). 
 
As expected, statin users had clearly lower total cholesterol and LDL cholesterol levels (mean [SE]: 2.3 
[0.05] versus 3.1 [0.05] mmol/L, P<0.0001), but lower HDL cholesterol (1.49 [0.03] versus 1.57 [0.03] 
mmol/L, P=0.026), respectively. On the other hand, indices related to glucose metabolism tended to be 
worse among statin users, who also had a twice higher prevalence of diabetes as compared to nonusers 
(19.0% vs. 9.4%, P=0.008), despite similar BMI and waist circumference. One-hour post-load glucose level 
measured in midlife was similar in users and nonusers of statins (mean 6.0, SE 0.1 mmol/L in both groups). 
Interestingly, plasma prealbumin level reflecting nutritional status was significantly (P=0.005) higher among 
statin users (257.9 [2.9] mg/L) than nonusers (246.3 [2.9] mg/L). The difference remained significant 
(P=0.034) when adjusted further for BMI and plasma high-sensitivity C-reactive protein level. 
 
Decreasing prealbumin showed a trend (P=0.050) for age-adjusted association with frailty in the whole 
cohort. Furthermore, highly significant (P<0.0001) age-adjusted decrease of peak expiratory flow (PEF) was 
seen with increasing frailty. 
 
However, no significant differences between statin users and nonusers were observed for various frailty 
indicators, including phenotypic frailty. Of note, statin users also reported significantly less musculoskeletal 
disorders than nonusers (P=0.048). We also compared the 8 scales of RAND-36 HRQoL instrument between 
statin users and nonusers, and after adjustment for age and multimorbidity, there was no significant 
difference in any of the HRQoL scales (Table 2). 
 
During the 7-year follow-up (2011-2018), 198 men (37.7%) died, 95 (36.7%) and 103 (38.7%) among statin 
users and nonusers. Age-adjusted HR of statin use was 0.96 (95% CI 0.72 to 1.30, P=0.81).  Further 
adjustment for current morbidity and midlife cholesterol (to reflect life-course cholesterol burden: mean 
6.7, SE 0.07 mmol/L and 6.1, 0.07 mmol/L among users and nonusers of statins in 2010/11, respectively, 
P<0.0001) diminished the point estimate but failed to reach statistical significance (HR 0.80, 95% CI 0.58 to 
1.11, P=0.19). Of note, multimorbidity in the whole cohort in 2010/11 was associated with a significant 41% 




In a real-life setting of a socioeconomically homogenous group of community-living octogenarian men, 
statin users had significantly more multimorbidity and derangement of glucose metabolism than nonusers. 
Still, statin users were not more frail, their quality of life was not impaired, and they had a similar mortality 
rate during a 7-year follow-up as compared to generally healthier nonusers of statins. A possible 
contributor to the resilience of statin users was the significantly higher prealbumin level pertaining to 
better nutritional health, a very important health factor among people aged 80 years and older.   
 
The present results further strengthen the evidence that statins are effective and safe way to improve 
prognosis also in octogenarians who have increased atherosclerotic cardiovascular disease (ASCVD) burden 
and risk factors and may thus relieve important concerns of statin use among oldest patients. Despite 
midlife cholesterol and current morbidity, the follow-up for 7-years showed a slight non-significant trend 
for statins decreasing overall mortality among men who were overrepresented with ASCVD. Our results are 
in accordance with a recent large meta-analysis of statins at different ages and among older individuals 
(16). Although statins were shown safe and effective in all age groups, the direct evidence for primary 
prevention among older people is less clear whilst statin therapy should be used by those with high risk for 
ASCVD. Our results support earlier studies showing neutral or improved effects of statin treatment 
irrespective of factors related to frailty, pains, HRQoL, or cognitive function in old age (3, 5, 17 - 22). 
 
A new and interesting finding among home-living statin users was the significantly higher plasma 
prealbumin level, which was independent of both BMI and C-reactive protein. Prealbumin has been used as 
an indicator of nutritional status (23), but it is also a negative acute-phase protein (24). Lower prealbumin 
levels have been reported to be associated with increased sarcopenia prevalence in older hospitalised 
patients independently of BMI and age (25, 26). Prealbumin levels below inflection point 265.9 mg/L were 
negatively associated with sarcopenia in hospitalised Chinese patients (26). Of note, in our study the mean 
prealbumin levels among statin users and nonusers were consistently fitted in the range and thereby 
independent association of nutritional marker with frailty vulnerabiliy can be assumed. Prospective studies 
with severe specific morbidities have reported survival benefit with increasing level of prealbumin (27, 28), 
and among patients with heart failure, less statin use was associated  with lower plasma prealbumin levels 
(28). We suggest that resilience and survival of older statin users would be at least partly associated with 
better preserved nutritional status reflected by higher prealbumin. There is also question arising whether 
statin-induced diabetes might reflect better nutrition and consequent resistance to the development of 
frailty. Detailed mechanisms underlying the finding need to be clarified in further studies. 
 
There are several limitations in our study. The homogeneity of the cohort is a strength (as it constricts 
variation in potential confounding factors) but also a limitation, in particularly in terms of the 
generalisability of findings. As the results apply to men and the response rate was 67.8% it is likely that 
non-responders may produce bias where the most frail people are underrepresented.  Although with 
frequent multimorbidity, one third of the cohort was assessed to be nonfrail. Also, the HRQoL in the cohort 
was relatively good. The results may thus not apply to most frail and institutionalised patients, although 
some epidemiologic studies have reported that prognostic benefit of statin treatment is independent of 
frailty status (17, 18). The survivorship bias needs to be accounted for as individuals with increased risk 
have been prescribed for statins causing unexpectedly lower mortality and more cardiovascular co-
morbidities. Moreover, the relationship of prealbumin with nutritional status may be confounded by 
clinician assessed indication and patient adherence. The exact duration of statin treatment was not known, 
but our earlier questionnaire surveys suggest that majority had been on a statin for at least 3 years, and a 
third for 10 years (unpublished observations). Among nonusers, 20% have been using statins earlier, but 




Among octogenarian men, statin use is associated with factors related to preserved resilience and survival 
despite more multimorbidity. The results may warn against deprescribing statins based on age alone. 
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Table 1.  Characteristics of participants by statin use a.  
variable  Nonusers, n=266  Statin users, n=259  P-value  
age, y, median (interquartile range)  83 (80-86)  82 (80-85) 0.073  
Lifestyle           
ever smokers, n (%)  125/265 (47.2)  108/257 (42.0)  0.12 (trend)  
nondrinker, n (%)  52 (19.8)  54 (21.0)  0.36 (trend)  
economic status good to satisfactory, %  99.7  100  0.77  
daily walking distance, %        0.81 (trend)  
- 0  1.2  3.0     
-< 1 km  29.1  26.1     
-1-3 km  55.0  56.0     
>3 km  14.7  17.1     
Nutrition           
BMI, kg/m2  24.8 (0.2)  25.1 (0.2)  0.18  
waist circumference, cm  96.4 (0.6)  97.3 (0.6)  0.29  
prealbumin, mg/L  246.3 (2.9)  257.9 (2.9)  0.005b  
lipids, mmol/L           
-          total cholesterol  5.2 (0.06)  4.4 (0.06)  <0.0001  
-          triglycerides  1.23 (0.04)  1.31 (0.04)  0.13  
-          HDL cholesterol  1.57 (0.03) 1.49 (0.03)  0.026  
-          LDL cholesterol  3.1 (0.05)  2.3 (0.05)  <0.0001  
Metabolic           
glucose, mmol/L  5.7 (0.09)  6.0 (0.09)  0.056  
insulin, mU/L  13.0 (0.9)  15.5 (0.9)  0.054  
HOMA-IR,  
(glucose mmol/L x insulin mIU/L)/22.5  
3.53 (0.33)  4.36 (0.33)  0.077  
QUICK1,  
1 / log(fasting insulin µU/mL) + 
log(fasting glucose mg/dL)  
0.34 (0.003)  0.33 (0.003)  0.029  
urate, umol/L  376.1 (5.6)  390.2 (5.6  0.077  
Inflammation           
hs-CRP, mg/L  2.8 (0.4)  2.6 (0.4)  0.21  
Frailty           
PEF L/min  441.2 (5.9)  439.6 (5.9)  0.85  
ALT U/L  18.7 (0.5)  18.8 (0.5)  0.93  
creatinine, µmol/L  95.8 (1.9)  99.3 (1.9) 0.19  
walk speed, m/s  0.86 (0.01)  0.84 (0.01)  0.39  
phenotypic frailty assessed        0.27 (trend)  
in 511 men, n (%)  
-nonfrail  92 (35.7)  97 (38.3)    
-prefrail  137 (53.1)  129 (51.0)     
-frail  29 (11.2)  27 (10.7)     
Morbidity, n (%)          
-diabetes  25 (9.4)  49 (19.0)  0.0008  
-hypertension  120 (45.1)  155 (59.8)  0.0007  
-CAD  19 (7.1)  117 (45.3)  <0.0001  
-cerebrovascular disorder  25 (9.4)  55 (21.2  <0.0001  
-PAD  27 (10.2)  30 (11.6)  0.29  
-heart failure  35 (13.2)  52 (20.2)  0.02  
-chronic lung disease 28 (10.5)  29 (11.2)  0.40  
-cancer  62 (23.3)  46 (17.8)  0.06  
-musculoskeletal disease  118 (44.4)  96 (37.2)  0.048  
mean number of diseases  1.7 (0.08)  2.4 (0.08) <0.0001  
multimorbidity (>2 diseases)  134 (50.4)  186 (72.1)  <0.0001  
Notes: Continuous variables are mean (SE). ALT = alanine amino transferase; BMI = body mass 
index; CAD = coronary artery disease; hs-CRP = high sensitivity C-reactive protein; HOMA-IR = 
Homeostatic Model Assessment for Insulin Resistance; PAD = Peripheral artery disease; PEF = 
peak expiratory flow; QUICK 1 = Quantitative Insulin Sensitivity Check Index.    
aAdjusted for age; analysis of covariance (ANCOVA) for continuous variables, Armitage test for 
trend in proportions. Logarithmically transformed values of triglycerides and C-reactive protein 
were used for comparisons. 
bP=0.034 after further adjustment for BMI and hs-CRP  
  
Table 2.  Age-adjusted RAND-36 scales by statin use.  
Scalea  Nonusers, n=266  Statin users, n=259  P-value b  
Physical Function  74.9 (1.3)  74.2 (1.4)  0.71  
Role Physical  71.4 (2.3)  68.4 (2.3)  0.35 
Role Mental  80.3 (2.0)  78.3 (2.1)  0.48  
Perceived Pain  80.6 (1.2)  80.5 (1.2)  0.94  
Vitality  76.5 (0.9)  75.7 (0.9)  0.57  
Social Function  87.1 (1.2)  85.0 (1.2)  0.21  
Mental Health  84.3 (0.9)  83.4 (0.9)  0.43 
General Health  61.7 (1.1)  57.9 (1.1)  0.015c  
a Scores are mean (SE), range from 0 (worst) to 100 (best).  
b Analysis of covariance (ANCOVA)  
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Appendix Table 1. Multidomain variables assessed in 525 HBS participants in 2010/11.  
Lifestyle-related  
Smoking  
Alcohol use  
Economic status  
Physical activity  
Nutrition- or Metabolism-related  
BMI  
Waist circumference  
Laboratory variables (plasma lipids, prealbumin)  




High-sensitivity C-reactive protein  
Frailty-related  
Peak-expiratory flow (PEF)  
Walk speed  
Laboratory variables (plasma ALT, creatinine)  
Phenotypic frailty  
Morbidity  
Self-reported diseases  
Multimorbidity  
   
   
 
 
 
 
  
 
